Let's see if the share price does the talking x |
Bri, you seem a little naive. It’s absolutely impossible to assess this RNS because we have no detail. This comes from a company which after a spectacular failure in phase III stated ‘the drug works’. They are absolutely not to be trusted and you have to wonder what on earth this data package contains… |
sounds excellent news though but wish they had given more details or released when they had the patent |
Hate to admit it but he has a point . |
So when is the bleedin trial going to start?!? That’s all that matters in the short term….. |
Well Nobby you ignore it if you want,I personally will be putting a lot more into this. |
£5 million market cap company realising this type of news,we could be £100's of million market cap if this leads to advances in the treatment of auto immune diseases. |
I laughed out loud! What sort of RNS is that?!? We know how p140 works and which patients to give it to….but we are not going to tell you how until we get the patent approved. Great thanks, that really makes it easy to assess whether this is a good investment or not!
Best ignored for now as it’s impossible to assess! |
This RNS sounds friggin amazing. |
Hows funding? |
Well I got a good feeling that the buying will continue as someone in the know stuck that £9K in this yesterday, hopefully. |
Nice £6K buy just before cop yesterday, let's hope it was someone in the know so to speak,well we are due news soon,we may be pleasantly surprised, maybe. |
chesty1 - sticky bun, currant bun, Chelsea bun or hot cross bun? |
Another stock for the bun |
kingston - just goes to show - you can't trust what the scientists tell you!
waterloo - as I keep pointing out to Nobby, it's McCarthy's job to keep the company running, which, despite serial failures by the scientists, he's succeeded in doing. I don't like what he does, but I think it's important to recognise where the problems lie, and it really isn't with McCarthy.
Or are you of the opinion that they should have just been allowed to go under? |
Some people really shouldn't be allowed to run companies., at least public ones. Macarthy being almost top of the list. (I can think of a few others).
Serial failures. |
The company was in the money on the warrants of INC, and if exercised at that time and sold the shares in the market would have made a tidy profit. Instead, the company paid £75k to extend the time limit for those warrants exercisable at 19.5 p, but INC's shares have tanked today to 3.5 p. Those warrants are under the water, and the £75k paid is now completely sunk. What a disaster of the decision made by the CEO of IMM!
Not only that he personally holds a lot of shares in INC so he has lost money there too, at least on paper. |
lol - wearing your heart on your sleeve, Nobby! It looks more like another science disaster to me. Which will have to be rescued, yet again, by another successful McCarthy fund raising :¬) |
Uh oh another McCarthy disaster! |
 Another article on the cell therapy approach. Looks increasingly as though that's the way lupus treatment will ultimately go.
BMS' CAR-T cracks down on lupus, achieving sustained responses in phase 1
Bristol Myers Squibb has linked its CD19-directed CAR-T cell therapy to sustained clinical responses in people with systemic lupus erythematosus (SLE), providing further evidence that the emerging class of candidates can reset the immune system.
Interest in using CAR-T cell therapies has taken off since German researchers posted data on five people with SLE in 2022. An update on the study in February showed eight SLE patients remained in remission. Patients had severe, progressive disease that was resistant to standard immunomodulating treatments. The researchers also reported data in systemic sclerosis (SSc) and idiopathic inflammatory myositis (IIM).
BMS is part of a wave of drug developers, both large and small, that hustled CD19-directed CAR-T cell therapies into autoimmune trials in the aftermath of the initial SLE data drop. The Big Pharma is sharing data at ACR Convergence 2024, where it is presenting results that go beyond the existing abstract.
[ ... ] |
Nobby - I came across this by accident:
hxxps://www.theatlantic.com/health/archive/2024/11/lupus-car-t-immune-reset-autoimmune-disease/680521
I can't get access to the original article, but from other reports it looks as though teclistamab might be a very valuable drug for lupus. Can you see the original paper? If it's cheap, effective, readily available, and approved (for at least something) then it might contribute to reluctance by Avion to run this trial. |
qaz - looks like you need a new body then. |
but my BODDDDYYYYYYYYYYYYYYYYY is telling me YESSSSSSSSSSS! |
My gut tells me no. ! |
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Hot Features
Premium
